Curriculum Vitae et Studiorum Ennio Carbone 2009

Curriculum Vitae et Studiorum
Ennio Carbone
2009

KAROLINSKA INSTITUTET
1) Teaching experience.
PEDAGOGIC PORTFOLIO
1.1) Undergraduate studies:
Sweden 1998. I was coordinating student group work at Karolinska Institutet
during the Immunogenetic Course for Biomedical science students. In 1999 I was
coordinator of a student group work in the Molecular Immunology Course for
medical students. In 2001 I was co-supervising together with Prof Britta Wahren
the master project of Annalinda Hultsrom (Hultström, Anna Linda, Natural killer
cell activity in HIV infection. Handl: Britta Wahren och Ennio Carbone,
Stockholm 17 april, 2001).
Italy: Since 1987 until 1990 I was engaged in the didactic activity offered by the
Chair of Immunology within the Immunology and Pathology Course for MD
students, University of Naples Federico II directed by Prof S. Zappacosta. From
the 1993 until the 1997 I was supplent Professor of Pathology at the Pharmacy
School University of Naples Federico II Specialization Course in Experimental
Pharmacology directed by Prof R. Di Carlo. Since 2001 to 2006, I was Assistant
Professor at the University of Catanzaro Magna Graecia (UMG) Medical School
and docent of Immunology and Pathology for the Medicine and Surgery Course
Students. Since 2006 I am Associate Professor of Pathology at UMG, resosable
docent for the following courses: Pathology within the Medicine and Surgery
graduation corse, Physiopathology at the Bioengeeniring graduation course,
Immunobiology at the Biotechnology graduation course, Immunology at Nursery
graduation course. Immunology at the International PhD program in Molecular
Oncology Experimental Immunology and development of new Therapy. I was
co-supervisor together with Prof S. Zappacosta the following student for the
diploma thesis experimental work : 1990 Dr. A. La Cava, 1999 Dr. A. Ottaiano,
1998 – 1999 Dr. C. Palomba, Dr I. Amendola. 2003 I was supervisor at
University of Catanzaro of the thesis laboratory work of Dr. N. Drmac. 2004 Dr.
MT Fulciniti, 2005 Dr. Tiziana Mandaliti.
1.2) Postgraduate teaching.
Since 2000 I am Faculty member of the: International Experimental Immunology
PhD program (University of Catanzaro Magna Graecia – Karolinska Institutet),
and the Molecular Oncology, Immunology and New Therapy Development
(University Magna Graecia, Karolinska Institutet, University of Friburg and
Roswell Cancer Park). Within these PhD program together with Docent Petter
Höglund (Karolinska Institutet) we have organised and directed a Joint Course
(UMG-KI) 2002, 2003, 2005, 2007. The venue of the Course was alternatively
Catanzaro and Stockholm. The 2002-2004 editions were focusing Tumorbiology
with special focus on innate immunological surveillance and immunotherapy of
cancer.Kursnummer (=anmälningskod) 1698. While the 2006 edition was
focusing on Combined anticancer therapy. All the Course organized within the
UMG-KI Joint PhD program have the standard time of 1 week full time course
with 7 lecture two hours each, student group work and with a written final

examination. The student that pass the final examination receive 1 credit (CFU).
This course has been really successful and the last edition (2007) have been held
in Friburg (Germany). The good results obtained with our Joint PhD course is
largely due to the mix between basic science and clinical problem. Under this
light I believe that our didactic work is new and original. The faculty of the Joint
PhD Course and program is formed by Docent from both side (UMG and KI).
The Italian PhD student of the UMG-KI international PhD program must spend at
least 1 year in the partner laboratory. Since 2006 international PhD students
trained in Italy are joining the MTC-KI. In particular Dr Kanth Tadepally
have completed his PhD period and now have been recruited as postdoc at the
MTC. A second round of PhD students will join the Karolinska Institutet
starting from September 2008.
Sweden, I was co-supervising two Postdoc; 1997 Dr Cristina Cerboni, 2000 Dr
Louise Berg.
Italy, I have been supervising the 4 year laboratory work of 4 PhD students and
1 Oncology Specialist MD work. The PhD students are: 1993-1997 PhD Jose
Terrazzano, 2003- Dr Lakshamikanth Tadepally, 2005- Dr Talib Hassan Ali,
2006 Rosanna La Rocca, 2006 Mario Galgani, 2006 Dr Shibu Krishnan, 2007
Rossana Talarico. While from the 2001 untill 2003 I was supervising Dr Paola
Neri specialization experimental thesis work. I have organized, lectured and
gived one seminar to the Course on The Molecular Basis of Autoimmune
Diseases and at the International PhD Course in Physiopathology of the
University of Naples Federico II and the International Experimental Immunology
PhD UMG-Catanzaro held in Naples the 10 th of October 2005. Experimental
immunology teaching at the Molecular Oncology, Experimental Immunology,
and Development of new therapy PhD program.
1.3) Continuing and advanced education plus specialist training
a) Time. Seven year Docent of Pathology within the Medicine and Surgery
graduation course (UMG), Seven years Docent of Pathology Nursery School
(UMG), Seven years Docent of the International PhD program in Molecular
Oncology, Experimental Immunology and development of New Therapy. Six
years co-director together with Prof Petter Hoglund of the International joint PhD
course UMG-KI. Thirteen years serving as docent of the “Ruggero Ceppellini”
Advanced Immunology School.
The independence level: All the didactic activities are carried out in completely
autonomy.
b) Type and variety. I am lecturing at the Medicine and Surgery graduation
course, Nursery, Biotechnology and Bioengineering and Computer Science
graduation courses (UMG), International PhD Program in Molecular Oncology
and Experimental Immunology (UMG-KI).
I was involved as Docent in the following Advanced Education Course organized
by the Advanced Immunology School “ Ruggero Ceppellini”: Level 1 (MD,
VetSc, Pharmacist) offered by the School:
L'immunità in patologia umana 95-96 Naples, November 1995-March 1996
L'immunità in patologia umana 2002 Naples, November - December 2002.
Level 2 (PhD, Post Doc, Junior and Senior Scientist):
HLA & Tumours Naples, 2-6 December 1996Course held at the Istituto
Nazionale Tumori Fondazione Pascale The Course Directors: S Ferrone

(Valhalla) & C Manzo (Napoli)The Faculty: E Carbone (Napoli) - M Colonna
(Basel) - P G Coulie (Louvain) - G B Ferrara (Genova) - S Ferrone (Valhalla) - P
Giacomini (Roma) - J Guardiola (Napoli) - K Kärre (Stockholm) - J Kaufman
(Compton) - R Kiessling (Stockholm) - M Maio (Aviano) - C Manzo (Napoli) - F
M Marincola (Bethesda) - L Moretta (Genova) - L Rivoltini (Milano) - B Seliger
(Mainz) - J Trowsdale (London);
Dendritic Cell PhysiologyPositano, 20-24 May 1999 Course held at the Hotel Le
Agavi The Course Director: P Ricciardi Castagnoli (Milano). The Faculty: S
Amigorena (Paris) - F Brière (Dardilly) - T Brocker (Freiburg) - E Carbone
(Stockholm) - C G Figdor (Nijmegen) - O J Finn (Pittsburgh) - G Girolomoni
(Roma) - F Granucci (Milano) - A Lanzavecchia (Basel) - C Maliszewski
(Seattle) - E Maraskovsky (Melbourne) - I McConnell (Edinburgh) - A O'Garra
(Palo Alto) - M Rescigno (Milano) - P Ricciardi Castagnoli (Milano) - E Simpson
(London) - S Sozzani (Milano) - R M Steinman (New York).
As Course Director: Innate Immunity in Self and Infectious Non-Self
Recognition Capo Miseno, 10-14 March 2005. Course held at the Hotel Club
Cala Moresca The Course Directors: G J Bancroft (London) – R Biassoni
(Genova) – E Carbone (Catanzaro) The Faculty: S Gordon (Oxford) – K Kärre
(Stockholm) – P M Kaye (York) – E A Levashina (Heidelberg & Strasbourg) – M
López-Botet (Barcelona) – A Mantovani (Milano) – L Moretta (Genova) – A
O’Garra (London) – P Parham (Stanford) – A Santoni (Roma) – J Trowsdale
(Cambridge) – A Velardi (Perugia).
Marie Curie EU supported “NK defence and therapy” Summer School, Bozava,
Dugi otok. 2007.
I have organized, lectured to the Course on The Molecular Basis of Autoimmune
Diseases and at the International PhD Course in Physiopathology of the
University of Naples Federico II and the International Experimental Immunology
PhD UMG-Catanzaro held in Naples the 10 th of October 2005.
Seminars:
1994 Microbiology and Tumorbiology Center (MTC), Karolinska
Institutet, Sweden.
1994 Department of Biology University of Roma “La Sapienza”
guest Prof. E. Piccolella
1997 Medical Research Council, Royal Postgraduate Medical School,
Hammersmith Hospital, London UK; guest Prof. E. Simpson
1997 Immunology Department Babraham Institute Cambridge, UK
guest Drs P. Kilshaw e G. Butcher.
1998 MTC Karolinska Institutet Stockholm, Sweden

2000 Neuroscience Department Huddinge University Hospital, guest
of Prof. H Blink. Sweden
2000 MTC Karolinska Institutet. Stockholm, Sweden.
2001 Department of Immunology, University of Stockholm,
guest Prof. Carmen Fernandez. Stockholm, Sweden.
2003 Chair of Hematology Department of Experimental Medicine.
Naples, guest Prof. B. Rotoli.
2004 Centrum for Infektionsmedicin (CIM) SSF, Huddinge
University Hospital, Huddinge, Sweden guest of Prof. HG
Ljunggren
2005 National Cancer Institut “Fondazione G. Pascale” Naples Guest
Dr. A. Boudillon.
2005 Department of Cellular and Molecular Pathology University of
Naples “Federico II” guest Prof. Enrico Avvedimento.
2006 Microbiology and Tumorbiology Center Karolinska Institutet,
guest Maria Joanhsson (immunobiology seminars)
Babraham Institute Cambridge UK
2007 Chairman of the Tumorimmunology Session of the Italian
Immunology Society National Congress Trieste.
2008 Max-Delbruck Centrum , Berlin Buch, guest Prof Thomas
Blamkestein.
Tutoring with problem solving learning. MD student of the Pathology course are
organized in study group with the task to enucleate from selected clinical case the
immunological aspect of the disease pathogenesis.
Educational experience can apply to more programmes: MD, Biotechnology,
Bioengeneering and Computer Science, Nursery graduation course. International PhD

program in Molecular Oncology, Experimental Immunology and New Therapy.
Advanced Immunology School “Ruggero Ceppellini”.
Participation in staff exchanges at Karolinska Institutet (Sweden) and University of
Catanzaro Magna Graecia (Italy). Within the framework of the Joint International
PhD Program.
c) Examinations. I am responsible for the final evaluation of the knowledge acquired
by MD, Biotechnology, Nursery, Bioengineering and Computer Science
undergraduate students by oral examination. All the educational activity within the
postgraduate courses are ending in the studying group oral presentation, where the
new knowledge acquired is evaluated.
d) Evaluation. The oral examination is based on a discussion of the lectures topic,
with special emphasis on evaluation of the student capability to extend and deepen the
knowledge on a given topic by literature search.
e) Other supervision/ mentoring. Sweden, I was co-supervising two Postdoc; 1997 Dr
Cristina Cerboni, 2000 Dr Louise Berg.
Italy, I have been supervising the 4 year laboratory work of 4 PhD students and 1
Oncology Specialist MD work. The PhD students are: 1993-1997 PhD Jose
Terrazzano, 2003- Dr Lakshamikanth Tadepally, 2005- Dr Talib Hassan Ali, 2006
Rosanna La Rocca, 2006 Mario Galgani, 2006 Dr Shibu Krishnan, 2007 Rossana
Talarico.
From the 2001 untill 2003 I was supervising MD, Dr Paola Neri Oncology
Specialization experimental thesis work. Experimental immunology teaching at the
Molecular Oncology, Experimental Immunology, and Development of new therapy
PhD program.
1.4) Formal Pedagogical experience.
Competence as a research fellow (“docent”): Not available in Italy.
1.5) Undergraduate course administration.
Experience within undergraduate courses,
Course organiser: MD graduation program, Pathology-Immunology course.
Biotechnology graduation program, Immunobiology Course
Bioengineering Informatic graduation program, Physiopathology Course
Nursery graduation program, Immunology.
Course organiser: Joint Course (UMG-KI) 2002, 2003, 2005, 2007. The venue of the
Course was alternatively Catanzaro and Stockholm. Each edition ten Karolinska
Institutet PhD student places were offered the participating students were selected
accordingly with their research project. A total of 40 students have taken part to this
Course. The 2002-2004 editions were focusing Kursnummer (=anmälningskod)
1698.
Admissions to undergraduate programmes and research schools.

Member of the Committee for the admission to the Medicine and Surgery School
University of Catanzaro “Magna Graecia” UMG.
Member of the Committee for the recruitment of PhD students in the International
Joint PhD program in Molecular Oncology, Experimental Immunology and
Development of New Therapy.
Globalisation have been taken in the shape of the International PhD program where a
number of slot for PhD student are dedicated to Indian and middle east researcher.
Since 2007 Member of the University of Catanzaro “Magna Graecia” Committee for
the international student exchange program
Since 2007 Member of the Medicine and Surgery Medical School International
Committee
1.6) Compilation of teaching material.
The teaching material is composed by power point presentation and original scientific
paper that are distributed before the lecture. All the didactic material are
downloadable from the website: http://www.unicz.it/immunology/
The material is compiled in complete autonomy
1.7) Pedagogical research and development work.
One Leonardo da Vinci-EU supported project have been submitted to the Commission
for funding. This project aim to strength the didactic cooperation between the UMG
and Karolinska Institute collaboration in the undergraduate studies. This project aim
to bring undergraduate or recently graduate MD, Biotechnology students to
Microbiology and Tumorbiology Center for 6 months-1 year stage with financial
support from the EU. The didactic activities will be strongly complemented with
laboratory work at the Karolinska Institutet.
The needs to bring together the theory provided by frontal lecturing with lab work is
required to finalize the students formation to the new technological acquisition in the
different field.
1.8) Honours and assessments of pedagogical work.
Assessment of pedagogical work on the basis of comments of directors of studies see
attachment.
1.9) Self evaluation of pedagogical efforts and assessment of pedagogical skills
within basic undergraduate education.
The characteristic of the didactic activity carried so far have been: high interactivity
between docent and the students, direct involvement of the student in the course
activity with the organization of study group, and literature search activities ending up
in a oral presentation. Finalization of the study to future professional activity. The
MD student are requested to use during the course and the final examination the new
knowledge acquired to decipher the molecular pathogenesis of the disease and the link
with the clinic semeiotic. For the biotechnology student the update on the new
available technology in the development of new drugs or research tools are highlight

in the lectures. The Courses and lectures are complemented by extra lectures held by
expert (PhD students) of a given topic or invited speakers.
The didactic materials are constantly updated. The lecture contents using as source
recent (not older than 3 years) state of the art review published on leading journal
(Nature, Annu Rev Immunol, Current Opinion in Immunology etc).

1.1) Scientific production:
1.1.1) Summary of all original paper.
KAROLINSKA INSTITUTET
SCIENTIFIC PORTFOLIO
1) La Rocca R, Fulciniti M, Lakshmikanth T, Mesuraca M, Ali TH, Mazzei V,
Amodio N, Catalano L, Rotoli B, Ouerfelli O, Grieco M, Gulletta E, Bond HM,
Morrone G, Ferrone S, Carbone E. Early hematopoietic zinc finger protein
prevents tumor cell recognition by natural killer cells. J Immunol. 2009 Apr
15;182(8):4529-37.
2) Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, Capanni
M, Umansky V, Paschen A, Sucker A, Pende D, Groh V, Biassoni R, Höglund
P, Kato M, Shibuya K, Schadendorf D, Anichini A, Ferrone S, Velardi A,
Kärre K, Shibuya A, Carbone* E, Colucci* F. NCRs and DNAM-1 mediate
NK cell recognition and lysis of human and mouse melanoma cell lines in
vitro and in vivo. J Clin Invest. 2009 Apr 6. pii: 36022.
3) Terrazzano G, Sica M, Gianfrani C, Mazzarella G, Maurano F, De Giulio B, de
Saint-Mezard S, Zanzi D, Maiuri L, Londei M, Jabri B, Troncone R, Auricchio
S, Zappacosta S, Carbone E. Gliadin regulates the NK-dendritic cell crosstalk
by HLA-E surface stabilization. J Immunol. 2007 Jul 1;179(1):372-81.
4) Markasz L, Stuber G, Vanherberghen B, Flaberg E, Olah E, Carbone E,
Eksborg S, Klein E, Skribek H, Szekely L. Effect of frequently used
chemotherapeutic drugs on the cytotoxic activity of human natural killer
cells. Mol Cancer Ther. 2007 Feb;6(2):644-54.
5) Wagner CS, Riise GC, Bergstrom T, Karre K, Carbone E, Berg L. Increased
Expression of Leukocyte Ig-Like Receptor-1 and Activating Role of UL18
in the Response to Cytomegalovirus Infection. J Immunol. 2007 Mar
15;178(6):3536-43.
6) Cerboni C, Achour A, Warnmark A, Mousavi-Jazi M, Sandalova T, Hsu ML,
Cosman D, Karre K, Carbone E. Spontaneous mutations in the human CMV
HLA class I homologue UL18 affect its binding to the inhibitory receptor LIR-
1/ILT2/CD85j. Eur J Immunol. 2006 Mar;36(3):732-41.
7) Carbone, E., Neri, P., Mesuraca, M., Fulciniti, M.T., Otsuki, T., Pende, D.,
Groh, V., Spies, T., Pollio, G., Cosman, D., Catalano, L., Tassone, P. Rotoli,
B., and Venuta , S. HLA class I, NKG2D and Natural Cytotoxicity Receptors
regulate Multiple Myeloma cell recognition by Natural Killer cells. Blood
2005:105.
8) Terrazzano G, Pisanti S, Grimaldi S, Sica M, Fontana S, Carbone E,
Zappacosta S, Ruggiero G. Interaction between natural killer and dendritic
cells: the role of CD40, CD80 and major histocompatibility complex class i

molecules in cytotoxicity induction and interferon-gamma production.
Scand J Immunol. 2004 Apr;59(4):356-62.
9) Hultstrom AL, Bratt G, Cosma A, Erfle V, Wahren B, Carbone E.
Autologous cytotoxicity of natural killer cells derived from HIV-infected
patients. Immunol Lett. 2004 Feb 15;91(2-3):155-8.
10) Cerboni C, Oberg L, Terrazzano G, Zappacosta S, Carbone E, Karre K.
Proliferative and cytotoxic response of human natural killer cells exposed to
transporter associated with antigen-processing-deficient cells.
Scand J Immunol. 2004 Feb;59(2):159-67.
11) Bond* HM, Mesuraca* M, Carbone E, Bonelli P, Agosti V, Amodio N, De
Rosa G, Di Nicola M, Gianni AM, Moore MA, Hata A, Grieco M, Morrone G,
Venuta S. Early hematopoietic zinc finger protein (EHZF), the human
homolog to mouse Evi3, is highly expressed in primitive human
hematopoietic cells. Blood. 2004 Mar 15;103(6):2062-70.
12) Berg L, Riise GC, Cosman D, Bergstrom T, Olofsson S, Karre K, Carbone
E.LIR-1 expression on lymphocytes, and cytomegalovirus disease in lung
transplant recipients. Lancet. 2003 Mar 29;361(9363):1099-101.
13) Terrazzano G, Zanzi D, Palomba C, Carbone E, Grimaldi S, Pisanti S,
Fontana S, Zappacosta S, Ruggiero G. Differential involvement of CD40,
CD80, and major histocompatibility complex class I molecules in cytotoxicity
induction and interferon-gamma production by human natural killer
effectors. J Leukoc Biol. 2002 Aug;72(2):305-11.
14) Odeberg J, Cerboni C, Browne H, Karre K, Moller E, Carbone E, Soderberg-
Naucler C. Human cytomegalovirus (HCMV)-infected endothelial cells and
macrophages are less susceptible to natural killer lysis independent of the
downregulation of classical HLA class I molecules or expression of the
HCMV class I homologue, UL18. Scand J Immunol. 2002 Feb;55(2):149-61.
15) Cerboni C, Mousavi-Jazi M, Wakiguchi H, Carbone E, Karre K, Soderstrom
K. Synergistic effect of IFN-gamma and human cytomegalovirus protein
UL40 in the HLA-E-dependent protection from NK cell-mediated
cytotoxicity. Eur J Immunol. 2001 Oct;31(10):2926-35.
16) Hultstrom AL, Hejdeman B, Leandersson AC, Bratt G, Carbone E, Wahren
B. Human natural killer cells in asymptomatic human immunodeficiency
virus-1 infection. Intervirology. 2000;43(4-6):294-301.
17) Nagy N, Cerboni C, Mattsson K, Maeda A, Gogolak P, Sumegi J, Lanyi A,
Szekely L, Carbone E, Klein G, Klein E.
SH2D1A and SLAM protein expression in human lymphocytes and derived
cell lines. Int J Cancer. 2000 Nov 1;88(3):439-47.
18) Terrazzano G, Romano MF, Turco MC, Salzano S, Ottaiano A, Venuta S,
Fontana S, Manzo C, Zappacosta S, Carbone E.

HLA class I antigen downregulation by interleukin (IL)-10 is predominantly
governed by NK-kappaB in the short term and by TAP1+2 in the long term.
Tissue Antigens. 2000 Apr;55(4):326-32.
19) Carbone E, Terrazzano G, Melian A, Zanzi D, Moretta L, Porcelli S, Karre
K, Zappacosta S. Inhibition of human NK cell-mediated killing by CD1
molecules. J Immunol. 2000 Jun 15;164(12):6130-7.
20) Cerboni C, Mousavi-Jazi M, Linde A, Soderstrom K, Brytting M, Wahren B,
Karre K, Carbone E. Human cytomegalovirus strain-dependent changes in
NK cell recognition of infected fibroblasts. J Immunol. 2000 May
1;164(9):4775-82.
21) Carbone E, Terrazzano G, Ruggiero G, Zanzi D, Ottaiano A, Manzo C, Karre
K, Zappacosta S. Recognition of autologous dendritic cells by human NK cells.
Eur J Immunol. 1999 Dec;29(12):4022-9.
22) Martin-Fontecha A, Assarsson E, Carbone E, Karre K, Ljunggren HG.
Triggering of murine NK cells by CD40 and CD86 (B7-2).
J Immunol. 1999 May 15;162(10):5910-6.
23) Carbone E, Ruggiero G, Terrazzano G, Palomba C, Manzo C, Fontana S,
Spits H, Karre K, Zappacosta S. A new mechanism of NK cell cytotoxicity
activation: the CD40-CD40 ligand interaction. J Exp Med. 1997 Jun
16;185(12):2053-60.
24) Carbone E, Terrazzano G, Colonna M, Tuosto L, Piccolella E, Franksson L,
Palazzolo G, Perez-Villar JJ, Fontana S, Karre K, Zappacosta S.
Natural killer clones recognize specific soluble HLA class I molecules.
Eur J Immunol. 1996 Mar;26(3):683-9.
25) Ohlen C, Hoglund P, Sentman CL, Carbone E, Ljunggren HG, Koller B,
Karre K. Inhibition of natural killer cell-mediated bone marrow graft
rejection by allogeneic major histocompatibility complex class I, but not class
II molecules. Eur J Immunol. 1995 May;25(5):1286-91.
26) La Cava* A, Carbone* E, Moscarella A, Barcova M, Salzano S, Zappacosta
S, Fontana S. A novel strategy of c-myc oncogene in NK activity regulation
not related to the W6/32 MHC class-I epitope. Int J Cancer. 1994 Jul
1;58(1):123-8.
27) Carbone E, Stuber G, Andree S, Franksson L, Klein E, Beretta A, Siccardi
AG, Karre K. Reduced expression of major histocompatibility complex class I
free heavy chains and enhanced sensitivity to natural killer cells after
incubation of human lymphoid lines with beta 2-microglobulin. Eur J
Immunol. 1993 Aug;23(8):1752-6. (Paper included in the thesis)

28) Hoglund P, Ohlen C, Carbone E, Franksson L, Ljunggren HG, Latour A,
Koller B, Karre K. Recognition of beta 2-microglobulin-negative (beta 2m-)
T-cell blasts by natural killer cells from normal but not from beta 2m- mice:
nonresponsiveness controlled by beta 2m- bone marrow in chimeric mice.
Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10332-6. (Paper included in the
thesis)
29) Carbone E, Racioppi L, La Cava A, Portella G, Velotti F, Zappacosta S,
Fontana S. NK and LAK susceptibility varies inversely with target cell MHC
class I antigen expression in a rat epithelial tumour system. Scand J Immunol.
1991 Feb;33(2):185-94. (Paper included in the thesis)
30) Racioppi L, Carbone E, Grieco M, Del Vecchio L, Berlingieri MT, Fusco A,
Boncinelli E, Zappacosta S, Fontana S. The relationship of modulation of
major histocompatibility complex class I antigens to retrovirus
transformation in rat cell lines.Cancer Res. 1988 Jul 1;48(13):3816-21. (Paper
included in the thesis)
31) Fontana S, Del Vecchio L, Racioppi L, Carbone E, Pinto A, Colletta G,
Zappacosta S. Expression of major histocompatibility complex class I antigens
in normal and transformed rat thyroid epithelial cell lines. Cancer Res. 1987
Aug 1;47(15):4178-83.
1.1.2) Summary of overview articles
1) Martin-Fontecha A, Carbone E.
The social life of NK cells.
Arch Immunol Ther Exp (Warsz). 2001;49 Suppl 1:S33-9. Review.
2) Nasca R, Carbone E.
Natural killer cells as potential tools in melanoma metastatic spread control.
Oncol Res. 1999;11(8):339-43. Review.
1.1.3) Summary of other scientific works.
Biassoni, R; Terrazzano, G; Dimasi, N; Carbone, E. Innate immunity in self
and infectious nonself recognition. Expert Review Clinic Immunol.Volume 1,
Number 2, July 2005. pp. 187-190(4)
1.1.4) Other scientific qualifications. Participation in international scientific
conferences.
1984 International Symposium on the Biological Significance of the Major
Histocompatibility Complex, Sorrento, Italy
1985 “9 th European Immunology Meeting” , EFIS, Roma, Italy

1989 “Autumn Meeting, British Society for Immunology”, London, UK.
1991 “7 th International Workshop on Natural Killer Cells”, Lyndigo, Sweden.
1991 “11 th European Immunology Meeting”, EFIS, Helsinki, Finland.
1992 “Keystone Symposia, Antigen Presentation Function and MHC”, Taos,
Nuovo Messico, U.S.A.
1992 “17th Meeting of the Society of the Natural Immunity “The NK cell and its
interaction with immune and non immune cells”, Taormina, Italy.
1995 “9 th International Congress of Immunology”, San Francisco, California,
U.S.A.
1996 “Soluble HLA Antigens: Functional and clinical significance” Genova, Italia.
(oral presentation)
1997 “13 th European Immunology Meeting”. Amsterdam, The Netherland. (oral
presentation)
1998 “4 th Workshop Internazionale di Immunità Naturale” Arlie Virginia, USA.
(Poster Oral presentation)
1998 “10 th International Congress of Immunology”, New Delhi, India.
1999 “NKT cell and CD1 Workshop”, San Diego, California. USA. (oral
presentation)
1999 “Society for Leukocyte Biology 15 th International Congress”, Cambridge.
(oral presentation)
2002 “7 th Workshop Internazionale di Immunità Naturale” San Juan, Puerto
Rico.
2003 “39 th Congresso Nazionale Società Italiana di Ematologia”, Roma. Italia.
2004 “4 h International Workshop on Innate Immunity ” Noordwijkerhoot,
The Netherland.

2005 “9 th Meeting The Society for Natural Immunity”, Poipu Beach, Kauai.
Hawaii, USA
2006 European Immunology Congress of the European Federation Immunology
Societies Meeting. (Oral Presentation)
2006 Heilderberg NK 2007 Symposium (Oral Presentation)
2007 Natural Immunity Meeting, Cambridge. UK, 4-9 April
2007 EU Marie Curie Summer School Botzava Croatia, 22-27 August Lecture
and Oral Presentation
*shared first name.
1.1.4 Total amount of quotation
a) citation index (765), citation per year (70).
b) The 10 most quoted paper of the last 10 years:
1) Carbone, E; Neri, P; Mesuraca, M, et al.
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple
myeloma cell recognition by natural killer cells
BLOOD Volume: 105 Issue: 1 Pages: 251-258. JAN 1 2005
Times Cited: 46
2) Bond, HM; Mesuraca, M; Carbone, E, et al.
Early hematopoietic zinc finger protein (EHZF), the human homolog to mouse
Evi3, is highly expressed in primitive human hematopoietic cells
BLOOD Volume: 103 Issue: 6 Pages: 2062-2070 MAR 15 2004
Times Cited: 14
3) Cerboni, C; Mousavi-Jazi, M; Wakiguchi, H, et al.
Synergistic effect of IFN-gamma and human cytomegalovirus protein UL40 in
the HLA-E-dependent protection from NK cell-mediated cytotoxicity
EUROPEAN JOURNAL OF IMMUNOLOGY Volume: 31 Issue: 10 Pages:
2926-2935. OCT 2001
Times Cited: 25
4) Nagy, N; Cerboni, C; Mattsson, K, et al.

SH2D1A and SLAM protein expression in human lymphocytes and derived cell
lines INTERNATIONAL JOURNAL OF CANCER Volume: 88 Issue: 3 Pages:
439-447. NOV 1 2000
Times Cited: 38
5) Berg, L; Riise, GC; Cosman, D, et al.
LIR-1 expression on lymphocytes, and cytomegalovirus disease in lungtransplant
recipients
LANCET Volume: 361 Issue: 9363 Pages: 1099-1101 Published: MAR 29 2003
Times Cited: 27
6) Carbone, E; Terrazzano, G, Melian, A, et al.
Inhibition of human NK cell-mediated killing by CD1 molecules
Source: JOURNAL OF IMMUNOLOGY Volume: 164 Issue: 12 Pages: 6130-
6137. JUN 15 2000
Times Cited: 16
7) Cerboni C, Mousavi-Jazi M, Linde A, et al.
Human cytomegalovirus strain-dependent changes in NK cell recognition of
infected fibroblasts JOURNAL OF IMMUNOLOGY 164 (9): 4775-4782 MAY 1
2000
Times Cited: 42
8) Carbone E, Terrazzano G, Ruggiero G, et al.
Recognition of autologous dendritic cells by human NK cells
EUROPEAN JOURNAL OF IMMUNOLOGY 29 (12): 4022-4029 DEC 1999
Times Cited: 93
9) Martin-Fontecha A, Assarsson E, Carbone E, et al.
Triggering of murine NK cells by CD40 and CD86 (B7-2)
JOURNAL OF IMMUNOLOGY 162 (10): 5910-5916 MAY 15 1999
Times Cited: 51
10) Carbone E, Ruggiero G, Terrazzano G, et al.
A new mechanism of NK cell cytotoxicity activation: The CD40-CD40 ligand
interaction JOURNAL OF EXPERIMENTAL MEDICINE 185 (12): 2053-2060
JUN 16. 1997 Times Cited: 121
1.1.5) Short summary of the findings in the most important articles in the past
ten years.
1) Cerboni C, Achour A, Warnmark A, Mousavi-Jazi M, Sandalova T, Hsu ML,
Cosman D, Karre K, Carbone E. Spontaneous mutations in the human CMV HLA

class I homologue UL18 affect its binding to the inhibitory receptor LIR-
1/ILT2/CD85j. Eur J Immunol. 2006 Mar;36(3):732-41.
This study represent the evolution of the research reported in paper 5) providing
molecular basis for the differences observed between CMV clinical and laboratory
strains in protecting infected cells to NK recognition. Here we show the UL-18 viral
protein cloned from CMV clinical isolates have a higher affinity for the NK inhibitory
receptor LIR-1 than the laboratory counterpart. The structural differences were
resolved structurally and surprisingly we found that UL18 alpha1 domain contribute
to the higher binding efficiency of the clinical isolates molecules. This data add new
insight in the association kinetics of the viral molecule with he inhibitory
immunoreceptor.
2) Carbone E, Neri P, Mesuraca M, et al.
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple
myeloma cell recognition by natural killer cells
Blood 105 (1): 251-258. 2005
This paper describe for the first time that autologous NK cells recognize and eliminate
multiple myeloma early stages cell targets. Moreover we demonstrate that the disease
progression leads to tumor variant selection expressing high levels of MHC class-I
levels and weak or no expression of NKG2D ligands.
3) Berg L, Riise GC, Cosman D, Bergstrom T, Olofsson S, Karre K, Carbone E.
LIR-1 expression on lymphocytes, and cytomegalovirus disease in lungtransplant
recipients. Lancet. 2003 Mar 29;361(9363):1099-101.
Here we show that one of the inhibitory NK receptor (LIR-1, CD85J) is upregulated
in heart and lung transplanted patient developing CMV disease. LIR-1 was previous
reported to recognize UL-18 a CMV MHC class I coded molecule. Our study was of
interest for a wide reader plate since it can be exploited to develop a better diagnostic
tool/kit for the early detection of CMV infection in transplanted patients.
4) Carbone E, Terrazzano G, Melian A, Zanzi D, Moretta L, Porcelli S, Karre K,
Zappacosta S. Inhibition of human NK cell-mediated killing by CD1 molecules. J
Immunol. 2000 Jun 15;164(12):6130-7.
This work was analysing:1) The NK-DC interaction molecular regulation focusing on
MHC-I like molecules CD1 and their role in presing Mycobacterium Tubercolosis
glycolipid antigens to NK cells. Our data demonstrate that CD1 molecules family
inhibit NK cell recognition of autologous DC and their presentation of lipid antigen
further inhibit NK cell cytotoxicity.
5) Cerboni C, Mousavi-Jazi M, Linde A, Soderstrom K, Brytting M, Wahren B, Karre
K, Carbone E. Human cytomegalovirus strain-dependent changes in NK cell
recognition of infected fibroblasts. J Immunol. 2000 May 1;164(9):4775-82.
This is the first evidence that CMV clinical strain not the laboratories infection inhibit
NK recognition of the infected cells. This paper help a lot the other investigator to

econcile apparent conflicting data so far reported in literature due to the heterogenous
use of clinical and laboratories virus isolates.
6) Carbone E, Terrazzano G, Ruggiero G, Zanzi D, Ottaiano A, Manzo C, Karre K,
Zappacosta S. Recognition of autologous dendritic cells by human NK cells.
Eur J Immunol. 1999 Dec; 29:4022-9.
This report was the first showing the autologous NK-DC interaction and for the first
time it was reported that human NK cells can recognize and kill autologous immature
DC , and the recognition was regulated by MHC-I and CD40 molecules. This paper
was pioneering the NK-DC immunoregulatory cross-talk field that now count several
hundred contributions (pubmed march 2006)
7) Martin-Fontecha A, Assarsson E, Carbone E, Karre K, Ljunggren HG.Triggering
of murine NK cells by CD40 and CD86 (B7-2). J Immunol. 1999 May
15;162(10):5910-6.
The in vivo and in mouse validation of the study reported below.
8) Carbone E, Ruggiero G, Terrazzano G, Palomba C, Manzo C, Fontana S, Spits H,
Karre K, Zappacosta S. A new mechanism of NK cell cytotoxicity activation: the
CD40-CD40 ligand interaction. J Exp Med. 1997. 185:2053-60
Here we addressed the question; which target cells molecules trigger NK cells
recognition? This question was rised timely since before of us the focus on NK
research was exclusively on the inhibitory NK cells ligands/receptor. For the first time
we demonstrated that specific activating NK ligands must be sensed by NK cells in
order to be triggered.
9) Carbone E, Terrazzano G, Colonna M, Tuosto L, Piccolella E, Franksson L,
Palazzolo G, Perez-Villar JJ, Fontana S, Karre K, Zappacosta S. Natural killer
clones recognize specific soluble HLA class I molecules. Eur J Immunol.
1996;26(3):683-9.
The paper collect evidences on the NK cytotoxicity inhibitory effect of serum MHC
class I.
10) Hoglund P, Ohlen C, Carbone E, Franksson L, Ljunggren HG, Latour A, Koller
B, Karre K. Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts
by natural killer cells from normal but not from beta 2m- mice:
nonresponsiveness controlled by beta 2m- bone marrow in chimeric mice. Proc
Natl Acad Sci U S A. 1991 Nov 15;88(22):10332-6.
This is a key stone of the research in the field of the missing self theory. Here we
demonstrated that conA blast T cells generated from beta2-/- mice are eliminated by
autologous NK cells. Therefore the simple absence of MHC-I molecules from the

healthy cell membrane shift their phenotype from NK resistant to NK susceptible.
Before this study only tumour cells with MHC-I defect were reported to be targeted
by NK cells.
1.2 Scientific collaboration and external research grants:
1.2.1 National and international collaborative projects.
a. New Combined Cancer Therapy, small molecules drugs (RITA) and immune
systema activation. Collaboration with Galina Selivanova MTC-KI and
Alfredo Budillon National Tumor Institute Naples.
b. Hematological Tumor progression and NK surveillance is a Italian Cancer.
Society (AIRC) funded project based on the following laboratories network:
University Magna Graecia (Carbone lab), Heidelberg German Cancer Society
(DKFZ) Dirk Schadendorf Lab, Cambridge Babrahm Institute Francesco
Colucci Lab
c. NKG2D ligand induction by mechanical stress is supported by MIUR and
involve the collaboration between Carbone lab , Enzo di Frabrizio from the
Trieste SISSA and Nanotechnology facility, Giacinto Scoles Chemistry,
Princeton University, Princeton, USA
d. NK and Myeloma recognition, Daniela Pende National Tumor Institute of
Genova, Roberto Biassoni G. Gaslini Fundation, Genova Italy, Veronika
Groh Fred Hutchinson Cancer Center Seattle, Soldano Ferrone Roswell
Cancer Park Buffalo USA, Andrea Velardi and Loredana Ruggieri
University of Perugia , Italy
e. NK-DC cross talk in autoimmune disease ; Bana Jabri University of Chicago
USA, Riccardo Troncone and Salvatore Auricchio, Serafino Zappacosta
and Jose Terrazzano University of Naples Federico II.
f. CMV and immunesurveillance: Louise Berg and Klas Kärre MTC-KI
1.2.2 Last five years grants:
2000-2001 “Toward a new therapy approach against leukaemia and Melanoma”
funded by Cancerfonden 250.000 (SEK)
2002-2004 “NK cell control of Multiple Myeloma progression” funded by Italian
Cancer Association (AIRC) 30.000 Euros
2003-2006 “NK cell control of hemathological tumor spreading” funded by AIRC.
30.000 Euros per year.
IT should be noted that in all the three projects I was the main applicant.
1.3 Supervision of doctoral candidates/postgraduate education.
1.3.1 Current supervision of doctoral candidates.
Please see also Didactic Portfolio related sections.

Currently I am supervising three PhD students, and one Fellowship holder. (2005
registration, half time seminar 2008)- Dr Talib Hassan Ali; (2006 registration, half
time seminar 2007) Rosanna La Rocca; (registration 2006) Mario Galgani,
(registration 2006) Dr Shibu Krishnan, (registration 2007) Rossana Talarico.
1.3.2 Supervision of doctoral candidates/postgraduate education.
Sweden, I was co-supervising two Postdoc; at MTC-KI I have supervised two
postdoc drs C.Cerboni (1997-1999) and L. Berg (2001-2003). Dr Berg now is holding
a VR Forskareassistentjanst position. 2008 Dr Lakshamantikanth Tadepally,
Italy, I have been supervising the 4 year laboratory work of 4 PhD students and 1
Oncology Specialist MD work. The PhD students are: 1993-1997 as student PhD Jose
Terrazzano and from 1997 to 2007 as postdoc. Dr Jose Terrazzano now holding a
university researcher position.
From the 2001 until 2003 I was supervising MD, Dr Paola Neri Oncology
Specialization experimental thesis work In the past I have supervised one PhD student
1.3.3 Work as lecturer and planner of postgraduate course and Development
work within postgradute studies.
I am faculty member in two international PhD program International experimental
Immunology and International Molecular Oncology Immunology and new Therapy
Development, I am lecturing in both courses.
Together with Prof. Hoglund we have organized , directed and teach in the Joint
annual Course UMG-KI for PhD student (see didactic portfolio). The
internationalization of the two PhD program was funded my the Italian Minestry for
university and research with 150.000 euros for each course.
1.4 Evaluation of others’ work:
a) Refereeing:
1) Journal Clinical Investigation
b) Editing:
2) Journal Leukocyte Biology
3) Blood
4) Clinical and Experimental Immunology
5) Cancer Immunology and Immunotherapy
1) associate editor of The Journal of immunology
c) Expert reviewer for grant giving organism:
1) Wellcome Trust
2) Dutch Cancer Society

3) Israelian Science Fundation
d) Scientific Society Membership :
1) Natural Immunity Society,
2) European Society of Tumour Immunotherapy,
3) Italian Society for Immunology, Clinical Immunology and Allergology (SIICA)
4) Ruggero Ceppellini Advanced School of Immunology.
e) Prizes:
1996 Best communication at the Joint Scientific Days University of Naples Federico
II, Schools of Medicine, Pharmacy, Veterinary.
1997 Best communication at the Joint Scientific Days University of Naples Federico
II, Schools of Medicine, Pharmacy, Veterinary.
2005 Cancer Research Prize from Associazione Italiana Ricerca Cancro (AIRC)-
Calabria Committee for the best cancer research work developed in the region.
1.5 Future Research Plan:
The future in the research means dissect the molecular, supramolecular and
submolecular (atomic) mechanism leading to physiological elimination of virus
infected or transformed cells by cytotoxic lymphocytes. In the recent past a
considerable knowledge have been produced in the NK cell field that now cry to be
translated in new therapy protocol.
The main aim of my research at MTC will be to develop integrated in vivo model
where exploit this knowledge.
At the University of Catanzaro “ Magna Graecia” (UMG) we have a highly integrated
multidisciplinary research lines based on the tight interaction between the
Tumorimmunology laboratory and the BIONEM (nanotechnology and science of
material) laboratory. The vision is to develop new research lines at Karolinska
Institutet that can explore the major medical disease immuno-pathogenesis using a
combination of Physic tools (Atomic Force Microscopy, RAMAN spectroscopy,
Optical Tweezers, 2-Photon Microscopy, FRET/FLIM application) and experimental
immunological approach (immunofluorescence, FACS, lympho-cytotoxicity, in vivo
metastatization assay, in vivo modulation of the immune response).
In this context I wish to integrate the most advanced knowledge on the biological
tumour-immunology mechanism and new technological tools as experimental
platform: Physic and Immunology. The vision is an integration between two different
knowledge; the molecular biology with the science of materials and biophysic.
The UMG offer a competitive integrated Bio-physic platform (Tumorimmunology
lab+BIONEM) while the Department of Microbiology Tumour and cell biology offer
a highly qualified center for the in vivo study of the tumour immune-rejection.

The integration between the Italian and Swedish lab will offer the possibility to
generate new classes of PhD students that have a new “hybrid” formation on basic
immunology and nanotechnology. The already existing Joint PhD program provide an
important starting base on which build up.
Research Lines:
Mechanical Stress, Cell Immunogenicity and NK cells sensitivity:
The focus is on the immune response of the cells (healthy versus cancer cells) to the
mechanical stress. The study will be carried out at single cell level and cell population
level. For the mechanical stress delivery at single cell level optical tweezers, while for
the mechanical treatment of cell population a nanopump for cell treatment have been
engineered. The prototype have been used in pilot experiment in Italy giving good
result in terms of human cell viability and immuno-phenotye modulation. To move in
vivo animal system we plan to enter in the nanopump and optical tweezers murine
tumour cell system (RMA, RMA-S). This project is ongoing within the Klas Karre
(Department of Microbiology, Tumor and Cell Biology) laboratory.
P-53, tumorimmunogenicity, NK recognition and new anticancer drug development.
The mechanism of DNA damage repair have been demonstrated to leads gene
activation encoding for NKG2D ligand and other NK cell recognized stress inducible
molecules. At MTC, Galina Selivanova ((Department of Microbiology, Tumor and
Cell Biology) selected a new small molecule drug (RITA) that can prevent P-53
degradation and thus increase its expression level in cancer cells. We are analysing
the effect of RITA on the induction of NK cell activating molecules.
HIV infection , HLA-C expression and ADCC therapy (Bill, Melinda Gates
Foundation, Grant Support).
New data have evidenced that upon HIV infection of T cells several HLA-class I
molecules are downregulated except HLA-C. Dr A. Beretta at the San Raffaele
University Hospital Milan have generated a HLA-C specific monoclonal antibody L-
31 and a grant application to Bill and Melinda Gates foundation is pending. A. Beretta
is mastering the molecular biology and genetic of HLA-C allele product while in the
past at Tumorbiology we have given some contribution on the relation between NK
cells recognition and HLA-C expression, moreover in collaboration with Britta
Wharen at SMI we published (paper n. 7) a study where we demonstrate that on HIV
infected CD4+ T lymphocytes the HLA-C expression is preserved. In case of success
of the Bill and Melinda Gates application the budget for the Carbone-NK unit will be
transferred at MTC-KI to start the project.

KAROLINSKA INSTITUTET
Curriculum Vitae
Name: Ennio Carbone
Date of Birth: 11/02/1961
Address: via Pigna 182 is Cbis , 80128 Naples, Italy
Telephone: +39 0961 3694088
Fax: +39 0961 3694090
E-mail: ennio.carbone@ki.se
Current Position:
a) Permanent Position, Associate Professor, University of Catanzaro “Magna
Graecia” Minestry of University and Research.
Previous Positions:
a) Permanent Position, Assistant Professor, University of Catanzaro “Magna Graecia”
Minestry of University and Research. (2000-2006)
b) EU-Marie Curie Postdoc fellow 1998-2000. (European Union grant, Karolinska
Institutet).
Education:
2006 Associate Professor at University Magna Graecia of Catanzaro and adjunct at
Microbiologo and Tumorbiology.
2004-to date Member of the Director Board of the Advanced Immunology School
“Ruggero Ceppellini” Naples.
2000-2006 University Researcher at the Experimental and Clinical Medicine
Department at the University of Catanzaro “Magna Graecia ”, School of Medicine
and Surgery. Appointed as Adjunct Member of the MTC Junior Faculty.
1999. Awarded with two years Research Grant from the Swedish Cancer Society
(Cancerfonden), two years Grant from the Svenska Lakeresallskapet, one year Grant
from Karolinska Institutet Stiftelser.
1998-1999 Two years EU-TMR grants fellowship at the MTC-KI Stockholm,

Sweden.
1996. Visiting researcher for six months at the MTC-KI
1995-1996 Awarded of a two year post doctoral fellowship at the National Tumor
Institute of Naples.
1993-1994 Guest Researcher at the Microbiology and Tumor Biology Centrum
(MTC) Karolinska Institutet, Stockholm within the Prof. K. Karre. Supported by one
year Italian Association for Cancer Research (AIRC) fellowship.
1989-1993 PhD Corse in Molecular Pathology, PhD Thesis Title: Regulation of Nk
cells by different HLA-class I isoforms. 1994, Rome, Thesis Defense.
Department Karolinska Institutet Stockholm.

KAROLINSKA INSTITUTET
LEADERSHIP, DEVELOPMENT AND WORKPLACE
RELATIONS PORTFOLIO PORTFOLIO
1.1 Formal education:
I was leading in Italy a research group from 1993 untill 1997 composed by 2
PhD and one MD student. Since 2001 to date I lead my research group composed
on the average of 6 persons (3PhD students, 1Fellowship recipient and 3
students).
The budget of the laboratory is about 100.000 euros per year including: the
personal cost and materials. The laboratory is supported by the Italian
Association for Cancer Research, the Department of Experimental and Clinic
Medicine (UMG), The EU-Grant STREP: DIPNA, the Italian Ministry for
University and Research.
Equal opportunity: Four out six laboratory member are female, 2 out six belong
from less favourites countries.
Environmental free lab: In our lab we don t use radioactivity materials, the waste
is differentially collected and we use procedure paper free for the document
exchange.
1.2 Strategic competence
I am collaborating with the CALMED srl a spin off company of the UMG as
expert in the product and market evaluation.
1.3 Leadership positions
a) Congress Organization:
1) “Innate Immunity in Self and Infectious Non-Self
recognition” 10-14 March 2005. Advanced School of
Immunology “Ruggero Ceppellini”
2) “The recrudescence of an old infectious disease:tuberculosis”
2-5 May 2007. Advanced School of Immunology “Ruggero
Ceppellini”
3) “Tumor Immune Escape 2008” 16-18 October 2008.
Advanced School of Immunology “Ruggero Ceppellini”
b) Board membership:
Member of the Board of the Directors of the Advanced
School of Immunology “Ruggero Ceppellini”.

1.4 Supervisor/lecturer/mentor
Sweden, I was co-supervising two Postdoc; 1997 Dr Cristina Cerboni, 2000 Dr
Louise Berg.
Italy, I have been supervising the 4 year laboratory work of 4 PhD students and 1
Oncology Specialist MD work. The PhD students are: 1993-1997 PhD Jose
Terrazzano, 2003- Dr Lakshamikanth Tadepally, 2005- Dr Talib Hassan Ali, 2006
Rosanna La Rocca, 2006 Mario Galgani, 2006 Dr Shibu Krishnan, 2007 Rossana
Talarico.
From the 2001 until 2003 I was supervising MD, Dr Paola Neri Oncology
Specialization experimental thesis work. Experimental immunology teaching at the
Molecular Oncology, Experimental Immunology, and Development of new therapy
PhD program.
1.5 Committee work
Participation in recruiting university boards:
2001 Member of the Italian Ministry Commission for the national competition
for one permanent position as assistant Professor at the Cosenza
University.
2002 Member of the University of Catanzaro “Magna Graecia” committee of the
commission for the recruitment of 4 PhD students within the Experimental
Immunology PhD program.
2003 Since may 2004 I am serving as Scientific secretary and Board of Directors
Member of the Immunology Advanced School Ruggero Ceppellini year
budget 50.000 euros
2007 Member of the International Committee of the University Magna Graecia
and of the Medical School.
2008 Member of the University of Catanzaro “Magna Graecia” committee of the
commission for the recruitment of 4 PhD students within the Experimental
Immunology PhD program
1.6 Active work on ethical issues, equal opportunities, the workplace
environment and environmental questions.
Equal opportunity: Four out six laboratory member are female, 2 out six belong
from less favourites countries.
Environmental free lab: In our lab we don t use radioactivity materials, the waste
is differentially collected and we use procedure paper free for the document
exchange.
1.7 Clinical leadership
not applicable
1.8 Workplace and social leadership competence.

Referees name: Prof R. Kiessling CCK, Karolinska Institutet. (Sweden, phone +46-
8-517 736 32)
Prof G. Klein MTC, Karolinska Institutet. (Sweden, phone +46-
8-728 6731)
Prof A. Santoni Università di Roma “La Sapienza” (Italy, phone
+39 06 44340632)
Prof. SHE Kaufman Max Planck Institut fur Infektionbiologi,
Berlin (Germany, phone +49 30 28 460 500)